Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Free Cash Flow came in at $292.0 million in Q2 2026, up 152.82% YoY from $115.5 million in Q2 2025, and up 500.04% on a QoQ basis from $48.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Free Cash Flow data on file, last reported at $292.0 million in Q2 2026.
- Quarterly Free Cash Flow rose 152.82% year-over-year to $292.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $819.9 million (up 1150.99% YoY) and the FY2025 annual result came in at $465.4 million, up 1192.73% from the prior year.
- Free Cash Flow rose to $292.0 million in Q2 2026, from $48.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $342.3 million in Q3 2023 to a low of -$189.1 million in Q1 2022.
- A 5-year average of $10.7 million and a median of -$60.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 130.04% — and 2025, when it jumped 757.62%.
- Tracing ALNY's Free Cash Flow over 5 years: stood at -$153.6 million in 2022, then jumped by 70.64% to -$45.1 million in 2023, then tumbled by 130.04% to -$103.8 million in 2024, then soared by 235.19% to $140.3 million in 2025, then jumped by 108.21% to $292.0 million in 2026.
- The last three Free Cash Flow figures came in at $292.0 million (Q2 2026), $48.7 million (Q1 2026), and $140.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 292.04 Mn |
| Jun 30, 2026 | 292.04 Mn |
| Mar 31, 2026 | 48.67 Mn |
| Mar 31, 2026 | 48.67 Mn |
| Dec 31, 2025 | 114.46 Mn |
| Dec 31, 2025 | 114.46 Mn |
| Sep 30, 2025 | 338.77 Mn |
| Sep 30, 2025 | 338.77 Mn |
| Jun 30, 2025 | 141.44 Mn |
| Jun 30, 2025 | 141.44 Mn |
| Mar 31, 2025 | -129.28 Mn |
| Mar 31, 2025 | -129.28 Mn |
| Dec 31, 2024 | -103.76 Mn |
| Dec 31, 2024 | -103.76 Mn |
| Sep 30, 2024 | 19.59 Mn |
| Sep 30, 2024 | 19.59 Mn |
| Jun 30, 2024 | 125.34 Mn |
| Jun 30, 2024 | 125.34 Mn |
| Mar 31, 2024 | -83.76 Mn |
| Mar 31, 2024 | -83.76 Mn |